Work

A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update

Year: 2024

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2024.07.422

Authors: Joyce Liu, David O'Malley, Els Van Nieuwenhuysen, Roisin O'Cearbhaill, Sara Bouberhan, Kathleen Moore, June Hou, Erika Hamilton, Suk-Young Yoo, Bin Wang, Mary Peterman, Tamara Schmidt, David Knorr, Israel Lowy, Thomas Uldrick, Elizabeth Miller

Institutions: Dana-Farber Cancer Institute, The Ohio State University, KU Leuven, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Sarah Cannon, University of Oklahoma Health Sciences Center, Columbia University, Regeneron (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403251237

FWCI: 0.395

Cites:

Cited by: 1

Related to: 10